This session explores the emerging role of drug-coated balloons (DCB) as a potential new standard for side branch treatment in bifurcation lesions. It focuses on selecting appropriate indications, optimal vessel preparation and delivery timing, and executing stepwise DCB strategies versus hybrid approaches to maximize clinical outcomes.

This session demonstrates the feasibility of transcatheter aortic valve implantation (TAVI) in patients with heart failure through a series of challenging cases. It covers sequential management of hypertrophic obstructive cardiomyopathy with aortic stenosis, advanced heart failure interventions, staged approaches in cardiogenic shock, and complex percutaneous interventions...

Addressing the complexities of ambiguous left main coronary lesions, this session elucidates the integration of physiology, intracoronary imaging, and CT scanning for comprehensive assessment. It highlights multimodality diagnostic strategies and decision-making frameworks to guide appropriate revascularization.

This session examines prediction, reduction, and avoidance of complications associated with TAVI procedures. It covers outcomes of second-valve implantation as a bail-out for valve migration, predictors of permanent pacemaker implantation post-TAVI from the LANDMARK trial, neurological event prognostics based on timing, and management of periprocedural cardiac...

Previous clinical trials suggested that ultra-thin strut biodegradable polymer sirolimus-eluting stent (BP-SES) may be associated with lower target lesion failure (TLF) when compared to durable polymer everolimus-eluting stents (DP-EES). However, the possible underlying mechanisms remain unclear. Therefore, the all-comers CASTLE study was designed to assess the...

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...